Administration of IL-1␤ results in a profound and long-lasting hypoglycemia. Here, we show that this effect can be elicited by endogenous IL-1 and is related to not only the capacity of the cytokine to increase glucose uptake in peripheral tissues but also to mechanisms integrated in the brain. We show that (i) blockade of IL-1 receptors in the brain partially counteracted IL-1-induced hypoglycemia; (ii) peripheral administration or induction of IL-1 production resulted in IL-1␤ gene expression in the hypothalamus of normal and insulin-resistant, leptin receptor-deficient, diabetic db͞db mice; (iii) IL-1-treated normal and db͞db mice challenged with glucose did not return to their initial glucose levels but remained hypoglycemic for several hours. This effect was largely antagonized by blockade of IL-1 receptors in the brain; and (iv) when animals with an advanced Type II diabetes were treated with IL-1 and challenged with glucose, they died in hypoglycemia. However, when IL-1 receptors in the brains of these diabetic mice were blocked, they survived, and glucose blood levels approached those that these mice had before IL-1 administration. The prolonged hypoglycemic effect of IL-1 is insulin-independent and develops against increased levels of glucocorticoids, catecholamines, and glucagon. These findings, together with the present demonstration that this effect is integrated in the brain and is paralleled by IL-1␤ expression in the hypothalamus, indicate that this cytokine can reset glucose homeostasis at central levels. Such reset, along with the peripheral actions of the cytokine, would favor glucose uptake by immune cells during inflammatory͞ immune processes.
T
here is evidence that immune-derived cytokines can mediate metabolic alterations during the course of infective, inflammatory, autoimmune, and neoplastic processes (1) (2) (3) (4) , either by acting locally or by interacting with different endocrine mechanisms (2, 3, 5) . Under physiological conditions, glucose is the principal and most readily available source of energy. When IL-1, a prototypic proinflammatory cytokine, is administered to mice, a profound and long-lasting hypoglycemia is observed. The hypoglycemic effect of IL-1 is not mediated by insulin, because it is clearly observed in insulin-resistant diabetic mice and rats; is not caused by glucose loss; and is independent from the anorexic effect of the cytokine (6) (7) (8) (9) (10) (11) (12) . IL-1-induced hypoglycemia might be explained by the capacity of this cytokine to stimulate glucose uptake in vitro in a variety of tissues such as adipose cells (13) , fibroblasts (14) , articular chondrocytes (15) , keratinocytes (16) , intestinal macrophages (17) , peritoneal mesothelial cells (18) , and glial cells (19) . Studies in vivo also show that overproduction of IL-1 results in increased 2-deoxyglucose uptake in all tissues tested, including lymphoid organs and the brain (20) . Several of the mentioned in vitro studies on the effect of IL-1 on glucose transport have been performed by using human cells, and injection of very low doses of recombinant IL-1␤ to patients with cancer induces a transient hypoglycemia (21) . Administration of low doses of LPS to healthy volunteers increases glucose utilization (22) and decreases glucose levels (23) . Because IL-1 is among the proinflammatory cytokines whose production is induced by LPS, these results indicate that IL-1 may also induce hypoglycemia in humans. IL-1␤-stimulated glucose transport is PKC-and p38 MAP-activation-dependent and is accompanied by increased expression and membrane incorporation of different glucose transporters (24) . The type of transporter affected depends on the tissue, for example, GLUT3 in the liver and brain and GLUT1 in chondrocytes (24) . Furthermore, IL-1 inhibits gluconeogenesis by inhibiting the activity of phosphoenolpyruvate carboxykinase and also mediates a reduction in hepatic glycogen content (12, 20) .
Besides these peripheral actions, there are indications that IL-1 can affect glucose homeostasis by acting at brain levels. Indeed, IL-1-mediated hypoglycemia develops against the enhanced output of counterregulatory hormones such as glucocorticoids, catecholamine, and glucagon (6, 9) and is very long lasting. Such a prolonged hypoglycemia is surprising, because the regulation of glucose levels in blood is one of the homeostatic mechanisms under the most tight feedback control at the level of the CNS. Studies have shown that injection of picogram amounts of IL-1 into the lateral brain ventricle induces hypoglycemia (10, 12) . There is also evidence for brain IL-1 in the CNS, particularly in the hypothalamus, where it is present in neurons, and the quantity is increased by LPS administration (25, 26) . These facts, together with the complex pattern of endocrine alterations caused by the cytokine, led us to hypothesize that IL-1, besides stimulating glucose transport and oxidation in the periphery, can also change the set point of CNS-mediated glucoregulation.
Here, we show that endogenous levels of IL-1 can induce hypoglycemia and trigger the expression of its own gene in the hypothalamus of normal and insulin-resistant mice. Furthermore, we provide evidence that IL-1 affects the set point for glucose homeostasis by acting at central levels.
IL-1 Induces a More Prolonged Hypoglycemia Than Regular Insulin.
We have compared the hypoglycemic effect of IL-1 with that of a dose of regular insulin that decreases glucose levels in a comparable magnitude. Fig. 1B shows the time kinetics of the effect of a single i.p. injection of 0.1 g of IL-1 and 0.25 units (11.4 g) of regular insulin on the glucose blood levels of normal mice. It is clear that insulin-injected mice returned to euglycemic values within 5 h, whereas the glucose levels of the mice that received IL-1 were still below the normal basal range 24 h later.
IL-1 in the Brain
Contributes to Peripherally Induced IL-1 Hypoglycemia. To explore the possibility that IL-1 induces hypoglycemia by acting in the brain, IL-1 was injected i.p. and IL-1ra (50 g) intracerebroventricularly (i.c.v.). When injected i.p., even 100 g of IL-1ra are not enough to significantly affect IL-1-induced hypoglycemia (see Fig. 1 A) . As shown in Fig. 2 , blockade of IL-1 effects in the brain significantly attenuated the hypoglycemia induced by peripheral administration of IL-1.
IL-1 Induces the Expression of Its Own Gene in the Hypothalamus of
Normal and Diabetic Mice. We then tested the possibility that IL-1 injected peripherally could result in the induction of its own gene in the hypothalamus and compared this effect with that of LPS. IL-1 induced IL-1 gene expression in the hypothalamus of normal and insulin-resistant, diabetic mice (Fig. 3A) . However, whereas IL-1-induced IL-1 gene expression in the brain was comparable in both types of mice, the effect of LPS was less marked in diabetic mice (Fig. 3B) . Interestingly, a correlation between IL-1 gene expression in the hypothalamus and glucose blood levels is established in both normal and db͞db mice when values of control-, IL-1-, and LPS-injected mice are plotted together (Fig. 3C ).
IL-1-Treated Mice Remain
Hypoglycemic After a Glucose Load. We have tested whether IL-1-induced hypoglycemia persists even after exogenous administration of glucose. Fig. 4A shows the results obtained when a glucose load was administered together with IL-1. After a transient increase in glucose blood levels, IL-1-treated mice were hypoglycemic for at least 4 h (Fig. 4A ). Fig. 4B shows the results of a similar experiment when the glucose load was given 2 h after IL-1 administration, i.e., when glucose levels were Ϸ50% reduced. We also included in these studies a group of mice injected with a dose of regular insulin that induced a hypoglycemia comparable with that of IL-1. The results clearly show that mice that received IL-1 returned to the reduced levels of glucose they had before the glucose load and remained at these levels during several hours. In contrast, insulin-injected mice approached basal euglycemic levels rapidly.
IL-1-Treated Diabetic Mice Have Reduced Glucose Levels Even After a
Glucose Load. We have previously reported that IL-1 can reduce glucose levels in db͞db mice. On this basis, we studied the effect of IL-1 when db͞ϩ and db͞db mice were subjected to a glucose load. Because, as we and others have shown, these mice are resistant to insulin, a group injected with this hormone was not included in these studies. The results obtained in the heterozygous, normoglycemic db͞ϩ mice are comparable with those obtained in C57BL͞6J mice: After a transient hyperglycemia due to the glucose load, IL-1-injected db͞ϩ mice remained hypoglycemic for at least 8 h (Fig. 4C) .
The basal levels of glucose in db͞db mice are more than twice those of normal mice, and the effect of IL-1 during a glucosetolerance test in these mice was quantitatively even more pronounced than in normal littermates (Fig. 4D) . After a transient further increase in glucose levels due to its exogenous administration, diabetic mice treated with IL-1 did not return to their previous hyperglycemic values, but glucose levels were within the basal range of normal animals during a remarkably prolonged time. Glucose levels of IL-1-injected db͞db mice were still significantly lower than those of vehicle-injected db͞db mice 24 h after the beginning of the experiment.
Occupancy of IL-1 Receptors in the Brain Is Necessary to Maintain
IL-1-Induced Hypoglycemia After a Glucose Load. We have investigated whether IL-1 affects the set point of glucoregulation at central levels. IL-1 and glucose were injected i.p. and IL-1ra was administered i.c.v. to block the receptors for the cytokine in the brain. Whereas IL-1-injected mice that received only the vehicle i.c.v. remained hypoglycemic for at least 8 h after the glucose load, those animals that received IL-1ra i.c.v. returned to euglycemic values 2 h after glucose administration (Fig. 5) .
IL-1 Resets Glucose Homeostasis at Brain Levels in db͞db Mice.
A study comparable with that in normal C57BL͞6J mice was performed in db͞ϩ and db͞db mice. Blockade of IL-1 receptors in the brain of db͞ϩ mice significantly reduced the hypoglycemia that followed a glucose load in IL-1-injected mice (Fig. 6A) . However, this effect was less marked than in C57BL͞6J mice. The basal glucose level of 7-to 8-week-old db͞db mice was between 450 and 600 mg͞dl When these mice received IL-1 and glucose i.p. and the vehicle i.c.v., a remarkable decrease (Ϸ5-fold) in blood glucose levels was observed for at least 8 h after the glucose load. This reduction was significantly less pronounced in diabetic mice treated in the same way but that received IL-1ra i.c.v. (Fig. 6B) . The same type of experiment was done at a more advanced stage of the disease, as reflected by glucose concentrations in blood between 700 and 900 mg͞dl when 12-to 14-week-old db͞db mice were used (Fig. 6C) . In these mice, a strong reduction in glucose levels was noticed during the first 8 h after the glucose load, independently of whether they received vehicle or IL-1ra injected i.c.v. However, a remarkable difference was detected between these two groups 24 h later. The average concentration of blood glucose in diabetic mice treated with IL-1 that received vehicle injected i.c.v. was Ϸ100 mg͞dl, and this value was maintained for at least 2 days. Four of six mice in this group died between 4 and 5 days after initiation of the treatment, most likely because of a relative hypoglycemia, because 24 h before death, their glucose concentrations were between 25 and 75 mg͞dl. In contrast, glucose levels in the blood of IL-1-treated mice that received IL-1ra i.c.v. started to increase 24 h after the glucose load and approached their previous basal levels 2 days later. No mortality was observed in this group of mice.
Discussion
The studies reported here provide evidence that the reduction of blood glucose levels induced by IL-1 in mice is not only based on increased glucose uptake and utilization in peripheral tissues but also determined by glucoregulatory mechanisms in the brain. These studies support the view that IL-1 resets glucose homeostasis at the level of the CNS. We have first established that endogenously produced IL-1 decreases glucose levels, results that are in line with those obtained in IL-1␣͞IL-1␤ knock out mice (27) . We also show that, even after a glucose load, hypoglycemia lasted longer in IL-1-treated mice than in those that received regular insulin. Furthermore, when glucose was injected 2 h after IL-1, i.e., when glycemia was rather low, hypoglycemic values were quickly regained and were maintained for several hours. These results agree with those obtained in IL-1ra knockout mice, showing that, under prolonged fasting, these animals display an accelerated response to a glucose load (28) . In a further step, we show that blockade of IL-1 receptors in the brain partially interfered with the hypoglycemic effect of IL-1 and that IL-1 transcripts in the hypothalamus were increased after peripheral administration of the cytokine or its inducer LPS. Such increases in IL-1 gene expression were negatively correlated with blood glucose levels. Taken together with studies showing that i.c.v. injection of picogram amounts of IL-1 induces hypoglycemia (10, 12), we concluded that this cytokine can alter glucose homeostasis by acting at central levels. The results discussed above suggested that IL-1 could change the set point of glucoregulation, which, as for other essential variables such as thermo-and osmoregulation, is orchestrated at central levels. To approach this issue directly, we blocked IL-1 receptors in the brain and studied the time needed by IL-1-treated normal and insulin-resistant db͞db mice to return to their basal glucose levels after a glucose load. As mentioned, IL-1-treated mice challenged with a glucose load needed several hours to recover from hypoglycemia. This prolonged delay occurs despite increased levels of counterregulatory hormones such as glucocorticoids, glucagon, and catecholamines (6, 9) . We show here that blockade of IL-1 receptors in the brain significantly diminished the capacity of peripherally injected IL-1 to induce hypoglycemia. Also after a glucose load, normal mice, in which IL-1 receptors in the brain were blocked, approached euglycemia more quickly than untreated mice. Comparable studies were done in db͞db mice. These animals, which are commonly used as a model of Type II diabetes, do not express functional leptin receptors and are obese and insulin-resistant. We performed glucose-tolerance tests at different stages of the disease in db͞db mice that received either vehicle or IL-1ra i.c.v., followed by a single i.p. IL-1 injection. After the short hyperglycemic episode due to the glucose load, the maintenance of reduced glucose levels induced by IL-1 was partially interfered with in young diabetic db͞db mice in which IL-1 receptors in the brain were blocked. The effect was comparable with that observed in control db͞ϩ mice. A different pattern was observed in older db͞db mice with a glycemia of Ϸ700-900 mg͞dl. After a further increase in glucose levels caused by the glucose load, the glycemia in IL-1-injected mice dropped to 25% of their basal values within 8 h. Later on, blood glucose concentration in mice that received IL-1ra in the brain was significantly higher than those of the db͞db animals that received the vehicle alone and approached the basal hyperglycemic levels. In contrast, db͞db mice that received IL-1 and the glucose load, and in which IL-1 could exert effects in the brain, remained hypoglycemic for at least 2 days, when they started to die without recovering from hypoglycemia. It appears that these mice did not tolerate a relatively low glucose level for a long time, because most of them died 4-5 days after the beginning of the treatment. Thus, the effect of IL-1 in the brain of insulin-resistant diabetic mice appears to be related to their initial glycemia and to be potentiated by exogenous administration of glucose.
It is surprising that animals injected with a low, subpyrogenic dose of IL-1 that have Ϸ50% reduction in glucose blood levels during several hours do not show neurological or other symptoms that characterize hypoglycemia. The finding that peripheral administration of IL-1 results in increased IL-1 mRNA expression in the brain, as shown here in normal and db͞db mice, considered together with previous reports showing that IL-1 stimulates glucose uptake by brain cells (19) and that 2-deoxyglucose incorporation in the brain is increased during a prolonged increase in IL-1 blood levels (20) , may provide a plausible explanation for this fact. Thus, it is conceivable that an increased central production of IL-1 contributes to protect neural cells by compensating the reduced glucose availability during IL-1-induced hypoglycemia. On the other hand, it should also be considered that an uncontrolled glucose uptake by the brain might be detrimental because of increased metabolism involving oxidative stress and ROS-induced neuronal damage, as it seems to occur during diabetic encephalopathy.
Control and regulatory systems operate efficiently to keep essential physiologic parameters within a programmed set point. However, a set point that is optimal under healthy conditions may need to be adjusted at other levels during diseases, in particular those in which the activity of the immune system is increased. The regulation of glucose levels is at the core of homeostasis, because glucose is the main source of energy for most cells. Essential immune processes such as endocytosis, phagocytosis, increased cell turnover, clonal expansion, production of numerous mediators, and generation of effector cells and molecules are very expensive in terms of energy (2, 3, 5, 29) . During acute physical stress, energy based on glucose supply needs to be deviated, for example, to muscles for an efficient ''fight or flight'' response. In contrast, IL-1, TNF-␣, or endotoxin administration decreases the rate of 2-deoxyglucose uptake by muscle tissue (30) . Indeed, glucose supply needs to be deviated toward immune cells for an adequate immune response. Our data support the hypothesis that IL-1 produced locally in inflamed͞infected tissue would stimulate glucose uptake and utilization by immune cells even during hypoglycemic conditions. Thus, IL-1 would play a relevant role in orchestrating the necessary central and peripheral adjustments of glucose homeostasis during acute immune processes.
The complexity of these adjustments is attested to by the fact that proinf lammatory cytokines induce an increased output of catecholamines, glucocorticoids, and glucagon, which increase glucose mobilization, and there is evidence that the effects of IL-1 are clearly deepened when these mechanisms cannot operate (6) . However, host responses mediated by counterregulatory hormones can only partially neutralize the hypoglycemic effect of IL-1. Insulin itself can also mediate a counterregulatory effect, because a clear reduction in the levels of this hormone is observed after administration of IL-1 to normal and fa͞fa rats (11) and to adrenalectomized animals (6). Thus, IL-1 triggers a reorganization of the main neuroendocrine mechanisms that control glucose homeostasis, an effect that is further indicated by the prolonged reduction of glucose blood levels that follows a glucose load in IL-1-treated animals. Considering that glucoregulation is orchestrated at central levels, the evidence obtained by blocking IL-1 receptors in the brain supports the hypothesis that IL-1 changes the set point of glucose homeostasis. One possible mechanism by which brain-borne IL-1 could contribute to maintain glucose levels within this reduced set point is by down-regulating counterregulatory neuroendocrine mechanisms. However, the molecular bases underlying the effect of IL-1 in the brain still need to be established. prevent amplification of genomic DNA. The forward primers (sequence 5Ј-3Ј) used were CAA CCA ACA AGT GAT ATT CTC CAT G (amplicon length 152 bp) for IL-1␤ (32) and CAA CGG GAA GCC CAT CAC CAT (amplicon length 66 bp) for glyceraldehyde-3-phosphate-dehydrogenase (GAPDH). The fluorogenic internal probes used were CTG TGT AAT GAA AGA CGG CAC ACC CAC C for IL-1␤ and TTC CAG GAG CGA GAC CCC ACT AAC for GAPDH. The reverse primer used were GAT CCA CAC TCT CCA GCT GCA for IL-1␤ and CCG GCC TCA CCC CAT TTG A for GAPDH. The comparative ⌬⌬C T method was used to calculate relative gene expression data, because we had determined in preliminary experiments that the amplification efficiencies of the target gene (IL-1␤) and the reference gene (GAPDH) are comparable. Thus, the IL-1␤ mRNA level was normalized to the GAPDH mRNA level in each sample. The value of control animals was arbitrarily set at 1.0.
Statistical Analysis. Results are expressed as mean Ϯ SEM. Data were analyzed by using one-way ANOVA, followed by Fisher's test for multiple comparisons. Correlations were analyzed by using the StatView 5.1 program, version 2000. Differences were considered significant when P values were Ͻ0.05.
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